Scarica l'app Stockscreener
0.70
18.45%
-0.1584
Dopo l'orario di chiusura:
.70
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AXDX Giù?
Forum
Previsione
Frazionamento azionario
Accelerate Diagnostics Inc Borsa (AXDX) Ultime notizie
AXDX stock touches 52-week low at $0.73 amid market challenges By Investing.com - Investing.com South Africa
AXDX stock touches 52-week low at $0.73 amid market challenges - Investing.com Australia
Accelerate Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com - Defense World
Accelerate Diagnostics Reports 2024 Financial Results - TipRanks
Antimicrobial Susceptibility Testing Market Expecting Huge Demand in Upcoming Years Accelerate Diagnostics - openPR
Accelerate Diagnostics Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Accelerate Diagnostics seeks FDA clearance for WAVE system By Investing.com - Investing.com Australia
Accelerate Diagnostics seeks FDA clearance for WAVE system - Investing.com India
InventHelp Inventor Develops Modified Single-Serve Coffeemaker (KXK-162) - The Malaysian Reserve
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance - PR Newswire
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results - PR Newswire
Accelerate Diagnostics Inc. (AXDX) reports earnings - Quartz
Accelerate Diagnostics, Inc SEC 10-K Report - TradingView
Accelerate Diagnostics (AXDX) Expected to Announce Quarterly Earnings on Thursday - Defense World
StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Major Microbial Identification Market Trend 2025-2034: Automated Systems Transform Microbial Identification... - WhaTech
Accelerate Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Accelerate Diagnostics CFO Patience David sells $583 in stock By Investing.com - Investing.com South Africa
Investor Network: Accelerate Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Accelerate Diagnostics CFO Patience David sells $583 in stock - Investing.com
Merger Agreement with BioSymetrics to Accelerate Biomarker Identification, Enhance Drug Discovery and Expand Precision Medicine Applications in Advanced Cancer Diagnosis and Treatment | FinancialContent Business Page - Financial Content
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine - The Manila Times
Renovaro and BioSymetrics Announce Definitive Merger - GlobeNewswire
Masimo (MASI) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com - Armenian Reporter
Axos Invest Inc. Purchases 54,293 Shares of Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) - Armenian Reporter
Antimicrobial Susceptibility Testing Market Advancements Highlighted by Analysis and Forecast to 2033: Mark... - WhaTech
Indaba Capital Management, L.P. Acquires Significant Stake in Ac - GuruFocus.com
BD to separate biosciences and diagnostics business - BioWorld Online
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Projected to Reach USD 6.5 Billion by 2035 at a 4.2% of CAGR | Future Market Insights, Inc. - Morningstar
Global Antimicrobial Resistance Surveillance Market to Reach USD 9.50 Billion by 2032, Growing at a CAGR of 5.47% - WICZ
Accelerate Diagnostics faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
Accelerate Diagnostics faces Nasdaq delisting risk - Investing.com
Global Antimicrobial Susceptibility Testing Market to Reach USD 4.8 Billion by 2035, Growing at a CAGR of 3.6% | Future Market Insights, Inc. - GlobeNewswire Inc.
Accelerate Diagnostics (NASDAQ:AXDX) Share Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Accelerate Diagnostics reports preliminary FY 2024 revenue of $11.7 million - MSN
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results - PR Newswire
Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test - Business Wire
GRIFFIN ASSET MANAGEMENT, INC. Reduces Holdings in Accelerate Di - GuruFocus.com
Aptitude Secures $10M+ to Accelerate Development of Point-of-Care and Over-the-Counter CT/NG/TV STI Test on Metrix® Platform - PR Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update - Defense World
0.55%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):